Technical Analysis for INO - Inovio Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Historical INO trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Fell Below 20 DMA | Bearish | -1.10% | |
Bollinger Band Squeeze | Range Contraction | -1.10% | |
Gapped Down | Weakness | -1.10% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -7.41% | |
Bollinger Band Squeeze | Range Contraction | -7.41% | |
Multiple of Ten Bearish | Other | -7.41% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -10.89% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
Down 3% | 2 days ago | |
Down 2 % | 2 days ago | |
60 Minute Opening Range Breakdown | 2 days ago | |
Up 2% | 2 days ago | |
Up 1% | 2 days ago |
Get this analysis on your stocks daily!
- Earnings date: 11/09/2020
Inovio Pharmaceuticals, Inc. Description
Inovio Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. The company's DNA-based SynCon technology enables the design of vaccines capable of providing cross-protection against new, unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company's clinical programs include human papillomavirus/cervical cancer (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus, hepatitis B virus, human immunodeficiency virus, and malaria vaccines. It is also advancing preclinical research for a seasonal/pandemic influenza vaccine, as well as other products. Inovio Pharmaceuticals, Inc. has collaboration and license agreements with VGX International, Merck, and ChronTech. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. in May 2010. Inovio Pharmaceuticals, Inc. was founded in 1983 and is headquartered in Blue Bell, Pennsylvania.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Infectious Diseases Cancers Prostate Cancer Clinical Research Influenza Coronavirus Hepatitis B Vaccine Vaccination Novi Leukemia Hepatitis C Immunodeficiency Hepatitis B Virus Hepatitis C Virus Influenza Vaccine Virus Malaria Papillomavirus Virology Cervical Cancer Avian Influenza Electroporation Seasonal/Pandemic Influenza Universal Flu Vaccine
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 33.79 |
52 Week Low | 3.14 |
Average Volume | 11,814,257 |
200-Day Moving Average | 13.78 |
50-Day Moving Average | 10.52 |
20-Day Moving Average | 9.39 |
10-Day Moving Average | 9.36 |
Average True Range | 0.68 |
ADX | 12.56 |
+DI | 22.08 |
-DI | 23.29 |
Chandelier Exit (Long, 3 ATRs ) | 8.99 |
Chandelier Exit (Short, 3 ATRs ) | 10.66 |
Upper Bollinger Band | 10.21 |
Lower Bollinger Band | 8.57 |
Percent B (%b) | 0.26 |
BandWidth | 17.47 |
MACD Line | -0.32 |
MACD Signal Line | -0.38 |
MACD Histogram | 0.0596 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 9.74 | ||||
Resistance 3 (R3) | 9.75 | 9.53 | 9.61 | ||
Resistance 2 (R2) | 9.53 | 9.34 | 9.52 | 9.57 | |
Resistance 1 (R1) | 9.26 | 9.22 | 9.25 | 9.25 | 9.53 |
Pivot Point | 9.04 | 9.04 | 9.03 | 9.03 | 9.04 |
Support 1 (S1) | 8.77 | 8.85 | 8.76 | 8.76 | 8.47 |
Support 2 (S2) | 8.55 | 8.73 | 8.54 | 8.43 | |
Support 3 (S3) | 8.28 | 8.55 | 8.39 | ||
Support 4 (S4) | 8.27 |